287 related articles for article (PubMed ID: 29558894)
41. Should Canada and the United States universally vaccinate infants against hepatitis B? A cost-effectiveness analysis.
Krahn M; Detsky AS
Med Decis Making; 1993; 13(1):4-20. PubMed ID: 8433635
[TBL] [Abstract][Full Text] [Related]
42. Probabilistic cost-effectiveness analysis of the long-term effect of universal hepatitis B vaccination: an experience from Taiwan with high hepatitis B virus infection and Hepatitis B e Antigen positive prevalence.
Hung HF; Chen TH
Vaccine; 2009 Nov; 27(48):6770-6. PubMed ID: 19735755
[TBL] [Abstract][Full Text] [Related]
43. An assessment of differences in costs and health benefits of serology and NAT screening of donations for blood transfusion in different Western countries.
Janssen MP; van Hulst M; Custer B;
Vox Sang; 2017 Aug; 112(6):518-525. PubMed ID: 28639703
[TBL] [Abstract][Full Text] [Related]
44. [Economic evaluation and prediction of hepatitis B immunization strategy in Shenzhen, China].
Sun PP; Zhang SX; Xia Y
Zhonghua Yu Fang Yi Xue Za Zhi; 2018 Jul; 52(7):743-747. PubMed ID: 29996303
[No Abstract] [Full Text] [Related]
45. Cost of illness for childhood diarrhea in low- and middle-income countries: a systematic review of evidence and modelled estimates.
Baral R; Nonvignon J; Debellut F; Agyemang SA; Clark A; Pecenka C
BMC Public Health; 2020 May; 20(1):619. PubMed ID: 32370763
[TBL] [Abstract][Full Text] [Related]
46. Cost effectiveness of hepatitis B vaccination strategies in Ireland: an economic evaluation.
Tilson L; Thornton L; O'Flanagan D; Johnson H; Barry M
Eur J Public Health; 2008 Jun; 18(3):275-82. PubMed ID: 18160389
[TBL] [Abstract][Full Text] [Related]
47. The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation.
Picot J; Jones J; Colquitt JL; Gospodarevskaya E; Loveman E; Baxter L; Clegg AJ
Health Technol Assess; 2009 Sep; 13(41):1-190, 215-357, iii-iv. PubMed ID: 19726018
[TBL] [Abstract][Full Text] [Related]
48. The economic burden of dementia in low- and middle-income countries (LMICs): a systematic review.
Mattap SM; Mohan D; McGrattan AM; Allotey P; Stephan BC; Reidpath DD; Siervo M; Robinson L; Chaiyakunapruk N
BMJ Glob Health; 2022 Apr; 7(4):. PubMed ID: 35379735
[TBL] [Abstract][Full Text] [Related]
49. Cost-effectiveness of universal hepatitis B virus screening in patients beginning chemotherapy for solid tumors.
Day FL; Karnon J; Rischin D
J Clin Oncol; 2011 Aug; 29(24):3270-7. PubMed ID: 21788556
[TBL] [Abstract][Full Text] [Related]
50. An economic assessment of pre-vaccination screening for hepatitis A and B.
Jacobs RJ; Saab S; Meyerhoff AS; Koff RS
Public Health Rep; 2003; 118(6):550-8. PubMed ID: 14563912
[TBL] [Abstract][Full Text] [Related]
51. Economic Evaluations of Child Nutrition Interventions in Low- and Middle-Income Countries: Systematic Review and Quality Appraisal.
Baek Y; Ademi Z; Paudel S; Fisher J; Tran T; Romero L; Owen A
Adv Nutr; 2022 Feb; 13(1):282-317. PubMed ID: 34510178
[TBL] [Abstract][Full Text] [Related]
52. Assessing cost-effectiveness of HPV vaccines with decision analytic models: what are the distinct challenges of low- and middle-income countries? A protocol for a systematic review.
Ekwunife OI; Grote AG; Mosch C; O'Mahony JF; Lhachimi SK
Syst Rev; 2015 May; 4():68. PubMed ID: 25963745
[TBL] [Abstract][Full Text] [Related]
53. Cost effectiveness of screening immigrants for hepatitis B.
Wong WW; Woo G; Jenny Heathcote E; Krahn M
Liver Int; 2011 Sep; 31(8):1179-90. PubMed ID: 21745300
[TBL] [Abstract][Full Text] [Related]
54. Prophylactic strategies for hepatitis B patients undergoing liver transplant: a cost-effectiveness analysis.
Dan YY; Wai CT; Yeoh KG; Lim SG
Liver Transpl; 2006 May; 12(5):736-46. PubMed ID: 16628682
[TBL] [Abstract][Full Text] [Related]
55. Limited hepatitis B immunoglobulin with potent nucleos(t)ide analogue is a cost-effective prophylaxis against hepatitis B virus after liver transplantation.
Singer GA; Zielsdorf S; Fleetwood VA; Alvey N; Cohen E; Eswaran S; Shah N; Chan EY; Hertl M; Fayek SA
Transplant Proc; 2015 Mar; 47(2):478-84. PubMed ID: 25769595
[TBL] [Abstract][Full Text] [Related]
56. The Economic Costs of Type 2 Diabetes: A Global Systematic Review.
Seuring T; Archangelidi O; Suhrcke M
Pharmacoeconomics; 2015 Aug; 33(8):811-31. PubMed ID: 25787932
[TBL] [Abstract][Full Text] [Related]
57. Economic Analysis of Children's Surgical Care in Low- and Middle-Income Countries: A Systematic Review and Analysis.
Saxton AT; Poenaru D; Ozgediz D; Ameh EA; Farmer D; Smith ER; Rice HE
PLoS One; 2016; 11(10):e0165480. PubMed ID: 27792792
[TBL] [Abstract][Full Text] [Related]
58. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation.
Shepherd J; Cooper K; Harris P; Picot J; Rose M
Health Technol Assess; 2016 Apr; 20(34):1-222. PubMed ID: 27135404
[TBL] [Abstract][Full Text] [Related]
59. Cost-of-illness of type 2 diabetes mellitus in low and lower-middle income countries: a systematic review.
Afroz A; Alramadan MJ; Hossain MN; Romero L; Alam K; Magliano DJ; Billah B
BMC Health Serv Res; 2018 Dec; 18(1):972. PubMed ID: 30558591
[TBL] [Abstract][Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
